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Determining the functional attributes of pancreatic transcription factors is essential to understand how the pancreas is specified distinct from
other endodermal organs, such as liver, stomach and duodenum, and to direct the differentiation of other cell types into pancreas. Previously, we
demonstrated that Pdx1-VP16 was sufficient to convert liver to pancreas. In this paper, we characterize the functional ability of another pancreatic
transcription factor, Ptf1a, in promoting ectopic pancreatic fates at early stages throughout the endoderm and later during organogenesis. Using the
transthyretin promoter to drive expression in the early liver region/bud of transgenic Xenopus tadpoles, we find that Ptf1a-VP16 is able to convert
liver to pancreas. Overexpression of the unmodified Ptf1a on the other hand has no effect in liver but is able to convert stomach and duodenum to
pancreas. When overexpressed at earlier embryonic stages throughout the endoderm, Ptf1a activity is similarly limited, whereas Ptf1a-VP16 has
increased activity. Interestingly, in all instances we find that Ptf1a-VP16 is only capable of promoting acinar cell fates, whereas Ptf1a promotes
both acinar and endocrine fates. Lastly, we demonstrate that, similar to mouse and zebrafish, Xenopus Ptf1a is essential for the initial specification
of both endocrine and exocrine cells during normal pancreas development.
© 2007 Elsevier Inc. All rights reserved.Keywords: Xenopus; Pancreas; Ptf1a; Specification; Transdifferentiation; Endocrine; Exocrine; OrganogenesisIntroduction
The vertebrate pancreas has its embryological origin as two
endodermal buds developing on the dorsal and ventral side of the
duodenum (Edlund, 2002; Kim and MacDonald, 2002). The
dorsal bud arises just below the notochord, while the ventral bud
develops adjacent to the hepatic diverticulum (Slack, 1995). The⁎ Corresponding author. Laboratory of Molecular Organogenesis, Institut de
Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC,
Canada H2W 1R7.
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doi:10.1016/j.ydbio.2007.01.027fusion of the two buds gives rise to a single mixed gland com-
posed of exocrine and endocrine cells. The exocrine pancreas is a
lobulated branched tissue, which includes acinar and ductal cells
that secrete and transport digestive enzymes into the duodenum.
The endocrine cells are grouped into islets of Langerhans
composed of five principal cell types, α, β, δ, ε and PP that
secrete glucagon, insulin, somatostatin, ghrelin and pancreatic
polypeptide hormones into the bloodstream.
In the amphibian Xenopus laevis, development of the pan-
creas proceeds in an almost identical manner to that seen in
mammals (Kelly andMelton, 2000). The dorsal bud is the first to
appear from a region just below the notochord at stage 35/36.
The ventral pancreas derives from two ventral buds adjacent to
787Z.H. Jarikji et al. / Developmental Biology 304 (2007) 786–799the liver that fuse at stage 37/38. At stage 39 morphogenetic
movements of the gastrointestinal tract reposition the pancrea-
tic rudiments leading to their fusion and formation of a single
organ. Signals from the mesoderm are required for pancreatic
differentiation, and development of exocrine and endocrine
cells occurs in a spatially and temporally distinct manner (Horb
and Slack, 2001, 2002; Kelly and Melton, 2000). Exocrine
cells are initially specified in the ventral pancreas, and endo-
crine cells in the dorsal. Amylase is first detected at stage 40
only in the ventral pancreas, and expression subsequently
spreads to the dorsal pancreas such that by stage 45 it is
present throughout the entire pancreas (Horb and Slack, 2002).
On the other hand, insulin is first expressed at stage 32 in the
dorsal pancreatic endoderm; expression in the ventral pancreas
is only detected at stage 47 (Horb and Slack, 2002; Kelly and
Melton, 2000). In contrast, the other endocrine markers glu-
cagon and somatostatin are not detected in the pancreas until
stage 45; though expression is present in the stomach at earlier
stages.
Several classes of transcription factors are involved in the
specification and differentiation of both endocrine and exo-
crine lineages (Habener et al., 2005). Although the number of
these transcription factors is significant, their precise roles in
the pancreatic transcriptional cascade and the downstream
targets they regulate remain unknown. Two of the earliest
acting transcription factors are Pdx1 and Ptf1a. Pdx1 is a
ParaHox gene that is expressed at the earliest stages in the
dorsal and ventral pancreatic buds as well as in the
duodenum (Wright et al., 1989); at later stages it is highly
expressed in beta cells, with lower levels also found in acinar
cells and all rostral duodenal cells (Jonsson et al., 1995).
Mice lacking Pdx1 do not develop a pancreas (Jonsson et al.,
1994; Offield et al., 1996) and mutations in the human homo-
logue, Ipf1, are associated with pancreatic agenesis (Stoffers
et al., 1997).
Ptf1a is a bHLH gene that is expressed in early pancreatic
progenitors (dorsal and ventral buds) (Kawaguchi et al., 2002),
but in adults is only expressed in acinar cells (Krapp et al.,
1996). The early induction of Ptf1a in the dorsal pancreas was
shown to require interactions with endothelial cells (Yoshitomi
and Zaret, 2004), while Fgf10 is necessary to maintain this
dorsal expression (Jacquemin et al., 2006). Loss-of-function
studies in mice have demonstrated that Ptf1a is essential for
acinar cell development and plays an important role in
endocrine cell development as well (Kawaguchi et al., 2002;
Krapp et al., 1998); in humans, PTF1A gene mutations are
associated with pancreatic and cerebellar agenesis (Sellick et
al., 2004). Similarly, morpholino knockdown studies in
zebrafish and more recently in Xenopus have shown that
Ptf1a is required for development of all acinar cells and a
subset of endocrine cells (Afelik et al., 2006; Lin et al., 2004).
It is however, only expressed in a subset of pancreatic pro-
genitors in the left ventrolateral endoderm and not in the dorsal
posterior endoderm (Lin et al., 2004; Zecchin et al., 2004).
Several reports have suggested that Ptf1a may function as a
master regulator of pancreatic cell fate. For example, pancreatic
cells lacking Ptf1a switch their fate and become duodenal(Kawaguchi et al., 2002), and loss of Hes1 leads to the
generation of ectopic Ptf1a expression in stomach, duodenum
and bile duct resulting in ectopic pancreas formation (Fukuda et
al., 2006). Similarly, overexpression of Ptf1a in Xenopus
embryos leads to an expansion of the pancreatic region, but
only within the Pdx1-expression domain, whereas combined
overexpression of Pdx1 and Ptf1a is sufficient to promote
acinar cell fates in posterior endoderm (Afelik et al., 2006).
Altogether, these results suggest that Ptf1a plays a central role
in the decision to become stomach, duodenum, bile duct or
pancreas.
Transdifferentiation is the conversion of one differentiated
cell type to another (Okada, 1991; Slack and Tosh, 2001). At
the molecular level, transdifferentiation is associated with a
change in the expression of master regulatory genes (Tosh and
Slack, 2002), of which Pdx1 is considered to be the pancreatic
master gene. Although it is expressed in and required for the
development of an endodermal domain broader than the
pancreas alone, Pdx1 can be considered to be part of the
transcription factor program associated with the adoption of
pancreas fate because it is expressed very early in the
outgrowth of the anlagen of this organ, and because there is
such an early abrogation of pancreas development in Pdx1−/−
mutants. In agreement with this, Pdx1 has been shown to
convert liver to pancreas (Meivar-Levy and Ferber, 2006).
Overexpression of Pdx1 in liver activates expression of
pancreatic endocrine and exocrine markers (Ferber et al.,
2000; Kojima et al., 2003; Miyatsuka et al., 2003; Tang et al.,
2006b) and is sufficient to prevent STZ induced hyperglycemia
(Ber et al., 2003; Ferber et al., 2000; Sapir et al., 2005; Zalzman
et al., 2003). We also showed that expression of a super-active
form of Pdx1 (Pdx1-VP16) in both human HepG2 cells and
Xenopus transgenics converts liver into pancreatic tissue
containing both exocrine and endocrine cell types (Horb et
al., 2003; Li et al., 2005). As seen with Pdx1, these Pdx1-VP16
expressing liver cells are capable of functioning as beta cells to
restore euglycemia in diabetic mice (Cao et al., 2004; Imai et
al., 2005; Kaneto et al., 2005; Tang et al., 2006a). Apart from
NeuroD, which was shown to induce islet neogenesis in the
liver (Kojima et al., 2003), the functional ability of other
pancreatic transcription factors to convert liver to pancreas has
not been fully explored.
We now report our results examining whether Ptf1a has
similar ability to convert liver to pancreas. Indeed, we find that
Ptf1a is able to promote ectopic pancreas formation in the
endoderm. We demonstrate that Ptf1a and Ptf1a-VP16 have
differential activities in converting endodermal organs to pan-
creas, dependent on the timing of overexpression. Further-
more, we find that Ptf1a-VP16 is only capable of promoting
an acinar cell fate, while the unmodified Ptf1a promotes both
acinar and endocrine cell fates. Last, we investigate the role
of Ptf1a in normal Xenopus pancreas development and find
that large-scale knockdown of Ptf1a function affects the
initial specification of both exocrine and endocrine cells.
Taken together, our results establish Ptf1a as being both
necessary and sufficient for endocrine and exocrine pancreatic
cell fate.
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Xenopus transgenics and transgene construction
All Xenopus transgenic constructs were cloned into the TTR-VP16:Elas-
GFP vector that was derived from TTR-Xlhbox8-VP16:Elas-GFP. Each
transgene was constructed as follows and confirmed by sequencing. TTR-
VP16-mPtf1a:Elas-GFP-mPtf1a cut EcoRI (mung bean nuclease) and cloned
into TTR-VP16:Elas-GFP cut XhoI (blunt). TTR-mPtf1a:Elas-GFP-mPtf1a cut
XbaI (blunt)–XhoI and cloned into TTR-Xlhbox8-VP16:Elas-GFP cut StuI–
XhoI. IFABP-mPtf1a:Elas-GFP-TTR-mPtf1a:Elas-GFP cut KpnI (blunt) and
ligated into IFABP-GFP cut BamHI (blunt). Same procedure followed for
IFABP-VP16-mPtf1a:Elas-GFP. TTR-Xptf1a:Elas-GFP-Xptf1a in pCR-Script
cut NotI–ClaI (blunt) and cloned into the TTR-Xlhbox8-VP16:Elas-GFP vector
cut ClaI–XhoI (blunt). Xptf1a-VP16-Xptf1a isolated as above and cloned into
VP16-N vector cut ClaI (blunt). TTR-Xptf1a-VP16:Elas-GFP-Xptf1a-VP16
cut NcoI–XbaI (blunt) cloned into TTR-Xlhbox8-VP16:Elas-GFP as above.
X. laevis transgenics were produced as previously described (Horb et al., 2003).
In later stages of our work, we switched the protocol for creating transgenics to
the I-SceI meganuclease method, with no change in activity (Pan et al., 2006;
Thermes et al., 2002). All functional portions (TTR-GeneX;Elas-GFP) of the
transgenes described above were cloned in between two I-SceI sites.
F0 Elas-GFP transgenics were generated using the Elas-GFP transgene as
described (Beck and Slack, 1999). F1 offspring were generated by crossing F0 a
female Elas-GFP adult with a wild-type male, whereas F2 offspring were
generated by fertilizing F1 female transgenic eggs with F1 transgenic sperm in
vitro. Germline transmission of the Elas-GFP transgene from these F1 adults is
found in 75% of the offspring when transgenic eggs are fertilized with F1
transgenic male sperm (n>300). When transgenic sperm is used to fertilize wild-
type female eggs, only 45% of the embryos are transgenic.
Isolation of Xenopus ptf1a
Degenerate PCR primers used to amplify a partial fragment of the bHLH
region of Xptf1a were based on the following peptides: PTLPYEKR, 5′-
TCCCCACCCTGCCCtaygaraarmg-3′ for the forward primer and ENEPPFEFV,
5′-CACGAACTCGAAAGGGggytcrttytc-3′ for the reverse primer. The PCR
product was cloned into the pCR-Script vector, and the sequence was used to
identify a Ptf1a open reading frame from the X. tropicalis genome assembly.
Based on the X. tropicalis Ptf1a sequence, the following primers were designed
to amplify the 5′end of X. laevis Ptf1a from stage 42 whole gut cDNA: forward
5′-CCGGCACCATGGAAACGGT-3′ and reverse primer 5′-ATCCTCAG-
GAGTCCACACT-3′. The PCR product was cloned into the pCR-Script vector
and ligated to the bHLH region of Xptf1a previously isolated by cloning into the
Not1-Bsu36I sites. The 5′ UTR of Xptf1a was cloned using 5′ RACE (BD
Biosciences). 5′ ready cDNA was prepared from stage 42 X. laevis whole
tadpoles (gift of G. Andelfinger). Two different reverse primers were designed:
the first primer was designed 720 bp from the start site 5′-ATCCTCAGGAGTC-
CACACT-3′ and the second 500 bp from the start site 5′-TGAGGAAGTTAAT-
GTAGC-3′. The PCR product was cloned into the pCRII vector (Invitrogen).
For cloning the X. laevis intron, we designed the following primers 60 bp
upstream and downstream of the predicted site of the intron: forward 5′-
GTACAGTCCGATCTGCCGCT-3′ and reverse 5′-CTCAGTTGCTTCTCAT-
CAGT-3′. We expected the X. laevis intron to be approximately 500 bp in size
since the X. tropicalis and mouse introns are 477 bp and 330 bp in length,
respectively. We amplified the X. laevis intron from stage 42 whole gut cDNA;
this can be accomplished since X. laevis cDNA frequently contains intronic
sequence. A single band of 832 bp was amplified and cloned into the pCRII
vector and sequenced; the intron being 712 bp long. Interestingly, when
compared to the X. tropicalis intron only one region of 43 bp was similar in
sequence, showing 84% nucleotide identity (data not shown). The accession
number for the complete cDNA sequence including 5′UTR is AY372268.
Embryological assays and whole mount In situ hybridization
Antisense morpholino oligonucleotides were designed by Gene Tools, LLC.
MO1 5′-CAACTGCTCCAGGACCGTTTCCATG-3′ targets the initiationcodon of Xptf1a. MO2 5′-ACGTTGGACTTACTTGTGCCCCGG-3′ targets
the exon-intron boundary. Synthetic mRNA transcripts were synthesized by SP6
in vitro transcription (mMessage machine, Ambion). Whole-mount in situ
hybridizations with single probes were performed as described using BM Purple
(Horb et al., 2003). Antisense digoxigenin probe for Xptf1a was synthesized
from Xptf1a in pCR-Script linearized with SacII and transcribed with T7 RNA
polymerase. Probes for other pancreatic markers were prepared as previously
described (Horb et al., 2003).
Real-time PCR
The Mx3005® multiplex quantitative PCR Thermal Cycler system from
Stratagene was used to monitor the real-time experiments and generated data
were collected and analyzed using the MxPro software provided with the
system. RNA was extracted from whole embryos and explants using Trizol,
cDNA prepared using Superscript reverse transcriptase (Invitrogen). Primers
were designed based on sequences available in Unigene and quality tested for
accuracy. Real-time PCR reactions were prepared using the QuantiTect SYBER
Green PCR kit from Qiagen. 10 μl of 2× QuantiTect SYBER Green PCRMaster
Mix was used for each reaction and primer concentration was optimized for
0.8 μM. PCR conditions were as follows 15 min activation at 95°, 30 s
denaturation at 94°, 1 min annealing at 58° and 30 s extension at 72° for 40
cycles. Real-time PCR values were normalized according to EF1α.Results
Previously, we demonstrated that Pdx1, when fused to VP16,
was sufficient to convert liver to pancreas (Horb et al., 2003),
but whether this attribute was a general characteristic of every
pancreatic transcription factor or limited to those that function
as master regulators of early cell fate was not explored. To
address this, we examined the transdifferentiation activity of
several pancreatic transcription factors using Xenopus trans-
genics. Both unmodified and VP16 fusions of seven different
pancreatic transcription factors, Hlxb9, NeuroD, Islet1, Pax4,
Pax6, Nkx2.2 and Ptf1a, were expressed in Xenopus tadpole
liver (Horb, unpublished). We created transgenic tadpoles
overexpressing each of these pancreatic transcription factors
using the double transgene construct previously described with
Pdx1-VP16 (Horb et al., 2003). Briefly, each gene was cloned
downstream of the liver transthyretin (TTR) promoter and the
resultant transgenic tadpoles examined for ectopic Elas-GFP
expression. In Xenopus, the TTR promoter directs expression
to the liver, stomach and duodenum after stage 44 as we
previously demonstrated (Figs. 4I and J in Horb et al., 2003);
this is after organ bud formation and cell fate specification, but
prior to complete maturation (Yan et al., 1990). The pancreas-
specific elastase promoter controls GFP expression providing
a real-time marker of pancreatic cell fate and showing that the
transgene is not silenced due to integration-site effects (Beck
and Slack, 1999; Horb et al., 2003). Though elastase is an
acinar-specific gene product, the elastase promoter element
(A+B+C) used here is the 213-bp fragment of the complete
promoter that is active in both endocrine and exocrine cells as it
lacks the endocrine repressive element (Kruse et al., 1993).
We defined positive transdifferentiation activity as ectopic
expression of GFP in transgenic tadpole liver and/or stomach/
duodenum (Horb et al., 2003); ectopic GFP expression repre-
senting a generic pancreatic fate. Of these fourteen constructs
(VP16 fusions and unmodified), we found that only two, Ptf1a-
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Elas-GFP.
In transgenic TTR-mPtf1a-VP16:Elas-GFP tadpoles, ectopic
GFP fluorescence is detected in the liver after stage 45 (Fig. 1C),
whereas in TTR-mPtf1a:Elas-GFP transgenics ectopic activa-
tion of Elas-GFP is detected in the stomach and duodenum and
not in the liver (Fig. 1B). Prior to this stage, Elas-GFP expression
is only found in the pancreas, and initial development of liver,
pancreas, stomach and duodenum occurs normally in both Ptf1a
and Ptf1a-VP16 transgenics. In Ptf1a-VP16 transgenic tadpoles
we find only partial conversion of liver, similar to that seen in
Pdx1-VP16 transgenics (Horb et al., 2003), whereas in Ptf1aFig. 1. Transgenic overexpression of Ptf1a and Ptf1a-VP16 promotes ectopic panc
expression only in the pancreas (p). No expression is seen in the stomach and duode
duodenum is evident and instead ectopicGFP is detected throughout this region (p+ep
Ectopic expression (ep) of Elas-GFP is seen opposite the pancreas in the liver. Stomach
and normal pancreas does not represent epithelial cells in the stomach or duodenum b
processing of samples for photography.) (D–F) AmylaseRNA expression in stage 46/4
(E) In TTR-Ptf1a transgenics ectopic amylase expression is now seen in the stomach an
Ectopic expression (ep) is seen in the livers of TTR-Ptf1a-VP16 tadpoles. (G–I) Insu
expressed in a punctate fashion within the pancreas. (H) In TTR-Ptf1a transgenics i
stomach, duodenum and pancreas (p+ep). The normal pancreas is seen bulging out to t
ectopic pancreatic tissue resembles the normal stomach. The liver (l) is normal. (I) Exp
expression is seen in the ectopic pancreas (ep). (J–L) Glucagon RNA expression in st
much like insulin. (K) In TTR-Ptf1a transgenics, ectopic glucagon expression is detec
ectopic glucagon expression is detected outside the pancreas.transgenics we find complete conversion of stomach and
duodenum (see below). The proportion of Ptf1a (n=77) and
Ptf1a-VP16 (n=36) transgenic tadpoles showing ectopic GFP
expression was 27% and 44%, respectively. This was quite
different from the results we previously obtained with Pdx1-
VP16, where we obtained 61% transgenics with ectopic pancreas
(Horb et al., 2003). The reason for these differences is unclear
but may reflect the fact that the Pdx1 acts earlier than Ptf1a in
pancreas development. These results demonstrate that the ability
to bring about transdifferentiation of liver to pancreas is specific
to Pdx1-VP16 and Ptf1a-VP16 and does not arise simply from
the use of the strong transactivator VP16 with any pancreaticreas formation. (A) Control St.44 Elas-GFP transgenic tadpole showing GFP
num (st+d). (B) St.45 TTR-Ptf1a:Elas-GFP transgenic tadpole. No stomach or
). The liver (l) is normal. (C) St.45 TTR-Ptf1a-VP16:Elas-GFP transgenic tadpole.
and duodenum are normal. (The punctate GFP expression in between the ectopic
ut are cells released from the ectopic pancreas due to mechanical abrasion during
7 whole guts. (D) In control whole guts amylase is only detected in the pancreas.
d duodenum that is fusedwith the normal pancreas (p+ep) and not in the liver. (F)
lin RNA expression in stage 46/47 whole guts. (G) In controls, insulin is found
nsulin expression is detected in the ectopic pancreatic tissue encompassing the
he left, while the ectopic pancreas is fusedwith it just to the right. The shape of this
ression of insulin is only seen in the pancreas of TTR-Ptf1a-VP16 transgenics. No
age 46/47 whole guts. (J) In controls, glucagon is expressed in a punctate fashion
ted in the stomach and duodenum (p+ep). (L) In TTR-Ptf1a-VP16 transgenics, no
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to convert other organs to pancreas is not a general characteristic
of every pancreatic transcription factor but is limited to those that
act during initial stages of cell fate specification (perhaps as
master regulatory genes).
The unmodified Ptf1a converts duodenum and stomach to
pancreas
Upon dissection of whole guts from TTR-Ptf1a:Elas-GFP
transgenic tadpoles after stage 46, we found no evidence of
stomach or duodenum, while the esophagus, intestine and liver
appeared normal. Instead we found a large region of pancreatic
tissue in the posterior foregut resulting from fusion of the
normal pancreas with ectopic pancreatic tissue generated from
the stomach and duodenum (Fig. 1B). We examined TTR-Ptf1a
transgenics for ectopically expressed pancreatic differentiation
markers. Interestingly, we detected expression of both endo-
crine and exocrine markers, amylase, insulin and glucagon,
within the ectopic pancreatic tissue emanating from the region
of the stomach, duodenum and pancreas (Figs. 1E, H, K). This
is in contrast to that seen in Ptf1a-VP16 transgenics, where only
exocrine markers were detected in ectopic pancreatic tissue.
These results demonstrate that overexpression of the unmodi-
fied Ptf1a after organogenesis of stomach, duodenum and liver
is sufficient to promote both ectopic pancreatic endocrine and
exocrine cell fates in stomach/duodenum, but not in liver.
To confirm transdifferentiation of stomach and duodenum to
pancreas, we examined whether there was loss of the stomach/
duodenum marker frp5 in Ptf1a transgenic guts. We found an
almost complete absence of frp5 expression in whole guts
isolated from TTR-Ptf1a transgenics as compared to control and
TTR-Ptf1a-VP16 transgenics (Fig. 2E). We did detect a small
amount of frp5 staining at the position corresponding toFig. 2. Effects of transgenic overexpression of Ptf1a-VP16 and Ptf1a on liver, stomac
stage 46/47 whole guts. (A) Control showing normal domain of TTR expression. N
normal. (C) Ptf1a-VP16 transgenic whole gut. Only a small domain of transthyretin e
of the stomach differentiation marker frp5 in stage 46/47 whole guts. (D) Frp5 exp
region (st+d), (E) Ptf1a transgenic whole gut. Almost no frp5 expression is detected
express frp5 and may be marking a small remnant of the duodenum (“d”). (F) Ptf1areappearance of the gut tube (“d”), at the posterior end of the
ectopic pancreatic tissue (Fig. 2E). We next examined whether
liver differentiation occurred normally and found normal
expression of the liver differentiation marker transthyretin in
Ptf1a transgenics (Fig. 2B). This was in contrast to the reduced
expression found in Ptf1a-VP16 transgenics (Fig. 2C), but in
agreement with the lack of ectopic Elas-GFP expression in the
livers of Ptf1a transgenics (Fig. 1C). Serial histological analysis
of whole guts isolated from TTR-Ptf1a transgenics confirmed
the loss of stomach and duodenum, and replacement with
pancreatic tissue (Figs. 3B–E). In anterior sections the eso-
phagus is evident, whereas in more posterior sections no gut
tube is present, and the entire region is replaced with pancreatic
tissue (Fig. 3D). In anterior sections, both the liver and pancreas
can be seen clearly (Fig. 3B); in more posterior sections, the
pancreas expands to encompass the whole region of the gut tube
that should have developed as stomach and duodenum (Figs.
3C,D). We have determined that the ectopic pancreatic tissue
replaces the stomach and duodenal tube for a distance of
168 μm (Figs. 3B–E). In conclusion, these results confirm that
unmodified Ptf1a is sufficient to cause transdifferentiation of
stomach/duodenum to pancreas, but has no effect in liver cells.
Ptf1a-VP16 is sufficient to convert liver to pancreas
To characterize the ectopic pancreatic tissue seen in Ptf1a-
VP16 transgenics, we determined which pancreatic cell types
(endocrine or exocrine) were present. Whole guts were isolated
from transgenic tadpoles at stages 46–47 and the expression of
both acinar and endocrine markers was examined by whole
mount in situ hybridization. Abundant expression of amylase
RNA was detected throughout the ectopic pancreas (Fig. 1F).
We did not detect expression of insulin or glucagon, although
occasionally a single positive cell was detected in the ectopich and duodenum. (A–C) Liver differentiation marker, transthyretin expression in
otice the size of the liver. (B) In Ptf1a transgenics transthyretin expression is
xpression is evident, located adjacent to the ectopic pancreas. (D–F) Expression
ression in control whole guts extends from the duodenum through the stomach
. A small region at the posterior end of the pancreas and ectopic pancreas does
-VP16 transgenic whole gut-frp5 expression is normal.
Fig. 3. Histological analysis of Ptf1a and Ptf1a-VP16 transgenic whole guts. (A) Control whole gut section stained for amylase showing normal stomach (st), pancreas
(p) and liver (l). (B–E) Single whole gut from TTR-Ptf1a:Elas-GFP transgenic tadpole was processed for histology after staining for amylase expression. 12-μm serial
sections numbers correlate to specific section, with number 1 corresponding to the first section obtained from the isolated whole gut. The posterior small intestine (si) is
evident in every section on the left side for orientation. (B) Section 5—esophagus (e), pancreas (p) and liver (l) are all present. (C) Section 11—the pancreas has almost
completely replaced the stomach and duodenum (p+e). A small portion of remaining stomach tube is evident but contains no recognizable stomach cells and the tube is
open. Part of the liver (l) can still be seen. (D) Section 18—no gut tube is evident, and a large ectopic pancreas (p+e) is found in place of the stomach and duodenum.
(E) Section 24—the small intestine (si) first reappears, with pancreatic tissue and liver still present. We measured the lack of stomach and duodenum from sections 10
to 24 to be 168 μm in total. (F) Section from Ptf1a-VP16 transgenic whole gut stained with amylase. The ectopic pancreas (ep) is seen fused with the liver, and the
normal pancreas adjacent but separate.
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represented a transdifferentiation event, we examined Ptf1a-
VP16 transgenics for loss of liver tissue. We found a large
decrease in expression of the liver differentiation marker
transthyretin (Fig. 2C). In the example shown only a small
piece of liver tissue remains fused with the ectopic pancreas. In
agreement with our previous results with Pdx1-VP16, we found
different phenotypes of liver to pancreas transdifferentiation,
from an almost complete loss of liver tissue to partial
conversions (data not shown). Histological analysis confirmed
ectopic pancreas fusion with liver in Ptf1a-VP16 transgenics
(Fig. 3F). In conclusion, these results demonstrate that Ptf1a-
VP16 is able to cause transdifferentiation of liver to pancreas,
but only to acinar cells and not endocrine cells.
Since the mouse Ptf1a protein shares only 60% overall
amino acid identity with Xenopus Ptf1a (see below), we decided
to examine whether Xenopus Ptf1a had similar transdifferentia-
tion activity. We therefore cloned Xenopus Ptf1a and created a
Xenopus Ptf1a-VP16 fusion and overexpressed it in transgenic
tadpole liver. Identical to that seen with mouse Ptf1a, Xenopus
Ptf1a-VP16 was sufficient to promote pancreatic acinar, and not
endocrine, fate in liver (data not shown). To determine whether
the placement of VP16 is important, we created both N- and
C-terminal fusions with Ptf1a but found no difference in activity
(data not shown). These results establish that placement of the
VP16 activation domain is not important, and that the mouse
and Xenopus proteins behave similarly.
We next examined whether Ptf1a and Ptf1a-VP16 transdif-
ferentiation activity is limited to stomach, duodenum and liver
by testing their ability to convert more posterior intestinal cells
into pancreas using the intestinal fatty acid binding (IFABP)
promoter (Sweetser et al., 1988). In Xenopus transgenics, the
IFABP promoter is active throughout the entire intestineposterior to the duodenum beginning at stage 44, but not in
the colon (Beck and Slack, 1999). Transgenic tadpoles were
generated bearing the transgenes IFABP-mPtf1a:Elas-GFP or
IFABP-VP16-mPtf1a:Elas-GFP and examined for ectopic
intestinal GFP expression. However, at no time (up to stage
48/49) did we observe ectopic GFP fluorescence in the intestine
(data not shown). These results demonstrate that the ability of
Ptf1a and Ptf1a-VP16 to convert other cell types into pancreas
is limited to the posterior foregut derivatives stomach/
duodenum and liver, respectively.
Ptf1a and Ptf1a-VP16 have similar capabilities in embryonic
endoderm, prior to organogenesis
To determine whether Ptf1a and Ptf1a-VP16 activity is
dependent on the differentiation state of endodermal cells, we
tested their ability to ectopically activate the Elas-GFP
promoter at earlier embryonic stages, prior to organogenesis.
Ptf1a mRNA was injected into the four vegetal blastomeres
of 8 cell transgenic F2 Elas-GFP X. laevis embryos (see
Materials and methods). The Elas-GFP transgene is active
from stage 32 and GFP fluorescence can be observed as early
as stage 38 in all pancreatic cells (Beck and Slack, 1999; Horb
et al., 2003). Overexpression of Ptf1a mRNA in vegetal
blastomeres, which was expected to diffuse broadly through-
out the endodermal progenitors, leads to ectopic activation of
the Elas-GFP transgene only in the stomach and duodenum
(Fig. 4C). No ectopic expression was detected either in the
liver or posterior endoderm, similar to that seen in transgenics.
We also observed a second milder phenotype of enlarged
pancreas, which contained a recognizable stomach and
duodenum of approximately normal size, in contrast to the
absence of these tissues as noted above (Fig. 4B). To confirm
Fig. 4. Overexpression of Ptf1a and Ptf1a-VP16 mRNA promotes ectopic and enlarged pancreas formation. Stages 42–44 dissected whole guts are shown in each
image. (A) Control F2 Elas-GFP transgenic tadpole whole gut. (B) Ptf1a-injected embryos showing expanded GFP fluorescence. Stomach (st), duodenum (d) and liver
(l) are normal, but the pancreas (p) is enlarged. (C) Ectopic pancreas formation in Ptf1a-injected embryo. The pancreas, stomach and duodenum (p+ep) form a large
ectopic pancreas expressing Elas-GFP. (D) Ptf1a-VP16-injected embryo showing ectopic GFP fluorescence throughout the anterior endoderm. (E–H) In situ
hybridization for elastase expression on isolated whole guts from (E) control, (F, G) Ptf1a-injected embryos and (H) Ptf1a-VP16-injected embryos. Notice expanded
and ectopic expression of elastase in Ptf1a and Ptf1a-VP16-injected embryos. (I–L) In situ hybridization for insulin in (I) control, (J, K) Ptf1a-injected embryos and
(L) Ptf1a-VP16-injected embryos. More insulin-expressing cells are detected in Ptf1a-injected whole guts, while there is a large decrease in insulin-expressing cells in
Ptf1a-VP16-injected whole guts (arrowheads). (M) Real-time PCR analysis of endocrine and exocrine markers in Ptf1a and Ptf1a-VP16-injected embryos for amylase
and insulin expression in control, Ptf1a-injected and Ptf1a-VP16-injected whole embryos at stage 35. Each bar is an average of 4 individual whole tadpoles. Amylase
expression is increased in both, while insulin expression is decreased in Ptf1a-VP16 and increased in Ptf1a-injected embryos. Purple—control tadpoles, red—Ptf1a
mRNA-injected tadpoles, yellow—Ptf1a-VP16-injected tadpoles.
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indicative of pancreatic differentiation, we examined injected
embryos for expression of elastase and insulin using whole
mount in situ hybridization. In Ptf1a-injected embryos we
found ectopic expression of both elastase and insulin in thestomach and duodenum (Figs. 4G, K). In the enlarged pan-
creata, we also found increased expression of both insulin and
elastase (Figs. 4F, J). We confirmed the expression level
changes of insulin and amylase in Ptf1a-injected embryos
using real-time PCR. Four individual embryos (control and
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ment with our in situ results, we found a 1.4-fold increase in
insulin expression and a 2.3-fold increase in amylase
expression (Fig. 4M). The other endocrine markers glucagon
and somatostatin are not expressed in the developing Xenopus
pancreas until stage 45; prior to this stage, however, both are
expressed in stomach and duodenal endocrine cells. To
examine glucagon and somatostatin expression in Ptf1a-
injected embryos, we collected whole guts at stage 45. Overall
we found reduced levels of both genes, which may be
indicative of the loss of stomach and duodenum (Figs. 5B, E).
We did detect relatively normal levels of expression of glu-
cagon and somatostatin in the ectopic pancreas, but unlike
insulin expression we did not detect increased expression of
these genes (Fig. 5). These results demonstrate that over-
expression of Ptf1a in early endoderm is sufficient to promote
pancreatic acinar and beta cell development and repress
stomach and duodenal endocrine cell development.
To determine what effects Ptf1a has on development of
adjacent endodermal organs, we examined Ptf1a-injected
embryos for expression of Frp5 (Pilcher and Krieg, 2002) and
Hex (Newman et al., 1997), markers of stomach/duodenum
and liver, respectively. In Ptf1a-injected embryos we found
normal expression of Hex, but little to no frp5 expression was
detected, indicating that stomach and duodenum did not
develop properly, while liver development was normal (Figs.
6C, G). In the enlarged pancreas phenotype, both frp5 and Hex
expressions were normal (Figs. 6B, F). We next examined
Ptf1a-injected embryos for excessive histone H3 expression to
determine if this activity is due to an overproliferation of
pancreatic cells. However, we did not detect any extra histone
H3 staining above control (data not shown). These results
indicate that Ptf1a is sufficient to respecify early stomach/
duodenal cells to pancreas, prior to their differentiation, but hasFig. 5. Development of glucagon and somatostatin expressing cells in Ptf1a and Ptf1
in control, Ptf1a and Ptf1a-VP16-injected embryos at stage 45. (B) Stomach and du
appears slightly reduced in Ptf1a-injected ectopic pancreas phenotype. (C) No glucag
expression. (E) Overall somatostatin expression is reduced in Ptf1a-injected embryos
is completely absent. (F) Somatostatin expression is completely absent in Ptf1a-VP1no effect in the developing liver bud or posterior endoderm,
identical to that seen in transgenics.
We next examined whether Ptf1a-VP16 activity is similarly
restricted in early endoderm as in transgenics. Similar to that
seen with the unmodified Ptf1a, overexpression of Ptf1a-VP16
within the entire endoderm resulted in ectopic Elas-GFP
expression only in the anterior endoderm (Fig. 4D); no ectopic
expression was detected in posterior endoderm in agreement
with the results obtained in transgenic overexpression. In these
embryos, we found Elas-GFP expression to encompass a much
greater area than that seen with Ptf1a, suggesting that Ptf1a-
VP16 was now able to respecify liver, stomach and duodenum
into pancreas (Fig. 4). We confirmed the loss of liver, stomach
and duodenum by examination of Hex and frp5 expression
(Figs. 6D, H). To determine which pancreatic cell types Ptf1a-
VP16 promoted, we examined endocrine and exocrine gene
expression in stage 40 injected embryos. In agreement with the
transgenic overexpression data, we found abundant expression
of elastase throughout the Elas-GFP domain (Fig. 4H).
However, to our surprise almost no insulin, glucagon or so-
matostatin expression was detected (Figs. 4L and 5C,F). To
determine more quantitatively the effects of Ptf1a-VP16 on
insulin expression, we examined initial insulin expression at
stage 35 using real-time PCR. In agreement with the results seen
in stage 40 whole guts, we found an 86% decrease in insulin
expression in Ptf1a-VP16-injected embryos at early stage 35
when beta cells are first specified (Fig. 4M). In contrast, in
Ptf1a-injected embryos, we found a 40% increase in insulin
expression at this same early stage. We also examined Ptf1a-
injected embryos for activation of acinar gene products. By real-
time PCR, we found a 1.8-fold increase in amylase expression
in Ptf1a-VP16-injected embryos (Fig. 4M). In conclusion, these
results demonstrate that Ptf1a-VP16 has greater activity in early
endoderm than at later organogenesis stages, but that itsa-VP16-injected embryos. (A–C) In situ hybridization for glucagon expression
odenal expression of glucagon is absent, while pancreatic glucagon expression
on expression is detected in Ptf1a-VP16-injected embryos. (D–F) Somatostatin
. Pancreatic expression appears normal, while stomach and duodenal expression
6-injected embryos.
Fig. 6. Effects of Ptf1a and Ptf1a-VP16 mRNA overexpression on organogenesis of liver, stomach and duodenum. (A–D) In situ hybridization for frp5 expression in
control, Ptf1a-injected embryos and Ptf1a-VP16-injected embryos. (B) Normal expression is seen in the enlarged pancreas phenotype from Ptf1a-injected embryos,
(C) whereas reduced expression is seen in the ectopic pancreas phenotype from Ptf1a-injected embryos. (D) No frp5 expression is detected in whole guts from Ptf1a-
VP16-injected embryos. (E–H) In situ hybridization for Hex expression in Control, Ptf1a-injected embryos and Ptf1a-VP16-injected embryos. (F, G) Normal
expression of Hex is detected in both enlarged and ectopic phenotypes from Ptf1a-injected embryos. (H) No Hex expression is detected in whole guts from Ptf1a-
VP16-injected embryos.
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fate. In addition, the fact that insulin is down-regulated by
Ptf1a-VP16 suggests that Ptf1a-VP16 alters the differentiation
program of endocrine precursors, such that they differentiate
along the acinar lineage.
Xenopus Ptf1a is essential for both exocrine and endocrine
pancreas development
To examine the functional role of Ptf1a in normal Xenopus
pancreas development, we isolated the X. laevis Ptf1a cDNA.
The deduced protein sequence of Xenopus Ptf1a shares
approximately 60% amino acid identity with other species,
with highest similarity found in the bHLH DNA binding
domain (data not shown). Similar to that seen by Afelik et al.
(2006), we find Ptf1a to be first expressed at neurula stages in
the midbrain–hindbrain region. Within the pancreatic endoderm
Ptf1a is first detected in both dorsal and ventral pancreatic
anlagen at stage 32 prior to overt morphogenesis and
differentiation (data not shown). The expression of Ptf1a in
both dorsal and ventral pancreatic buds prior to differentiation
suggests that it may play a fundamental role in early cell fate
specification of both endocrine and exocrine cells.
To determine if Ptf1a is essential for early pancreas
development, we used antisense morpholinos to block
translation and splicing of Ptf1a. A morpholino overlapping
the translation start site of Ptf1a was designed (MO1) based
on 5′UTR sequence, which we cloned using 5′ rapid
amplification of cDNA ends (see Materials and methods). A
second morpholino (MO2) was also designed to the exon–
intron boundary to inhibit splicing of the Ptf1a RNA (see
Materials and methods). We examined the efficacy of this
second morpholino by determining what effects it had onsplicing of the Ptf1a transcript. Injection of MO2 prevented
splicing of the primary Ptf1a transcript leading to inclusion of
the single intron (Fig. 7R). We were still able to detect some
of the proper splice transcript in MO2-injected embryos
suggesting that the single morpholino was unable to
completely inhibit Ptf1a translation; this may explain the
reason for a more severe phenotype being found with co-
injection of both morpholinos. To specifically target loss of
Ptf1a to the region of the embryo where it is selectively
expressed in the pancreatic endoderm, and avoid any indirect
effects of reducing protein levels in neural tissue, another site
of robust Ptf1a expression, we injected Ptf1a morpholinos
into all four vegetal blastomeres of 8 cell Xenopus embryos.
The antisense morpholinos are fluorescently labeled thus
allowing us to identify rapidly whether the injection was
properly targeted to the anterior endoderm. Embryos were then
allowed to develop to tadpole stages and analyzed for any
abnormalities.
Embryos injected with 40 ng of either MO1 or MO2
developed normally through gastrula, neurula and tail bud
stages. However, at tadpole stages the gut developed
abnormally with almost no recognizable pancreas (Fig. 7).
At stage 45 approximately 50% of injected embryos have a
small dorsal nub of tissue remaining, while the other 50%
seem to completely lack any obvious pancreatic outgrowth
(data not shown). Expression of acinar differentiation markers
was completely lost (Figs. 7A–C), while insulin expression
was reduced substantially (Figs. 7E–G). Interestingly, even in
those embryos with no discernable pancreatic tissue, several
insulin-expressing cells can be detected. These results would
therefore seem to suggest that Ptf1a is not essential for
endocrine cell development. Alternatively, it is possible that
since we are looking at insulin expression 4 to 5 days after
Fig. 7. Elastase expression is absent in Ptf1a morphants, while insulin expression is reduced at late stages, but absent at early stages. (A–D) Whole mount in situ
hybridization for elastase RNA expression in control and Ptf1a-MO dissected whole guts at stage 42. Elastase expression is not detected in either single or double
morpholino-injected guts. (E–H) Whole mount in situ hybridization for insulin RNA expression in control and Ptf1a-MO whole guts. (F, G) Insulin expression is
decreased in both single morpholino injections. (H) In embryos injected with both morpholinos together insulin expression is also reduced, but still present. (I–L)
Initial insulin expression is lacking in Ptf1a morphants. Insulin RNA expression by whole mount in situ hybridization in control and Ptf1a-MO-injected embryos at
stage 35. Inset in each panel is the low power view. (I) Control tadpole showing normal punctate insulin expression in the dorsal pancreas (arrow). (J, K) Insulin
expression is reduced in single morpholino-injected embryos but (L) completely lacking in double morpholino-injected embryos. (M–P) Expression of the liver
marker Hex is normal in both single and double Ptf1a morpholino-injected embryos. (Q) Real-time PCR analysis of insulin expression in control and Ptf1a-MO-
injected embryos at stage 35 confirms insulin reduction in single and double morpholino-injected embryos. Each bar is an average of four individual tadpoles. There is
a 50–60% reduction in single morpholino tadpoles (40 ng), but an almost complete absence in the double morpholino tadpoles (20 ng each). (R) RT-PCR analysis of
splicing in control and MO2-injected embryos showing the inhibition of splicing by MO2. Loading control was established with EF1α (not shown). Primers were
designed flanking the single Ptf1a intron.
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Fig. 8. Mouse Ptf1a rescues the Ptf1a-morpholino induced phenotype. (A)
Control whole gut showing elastase expression in the pancreas. (B) In Ptf1a-MO
whole guts elastase is absent. (C, D) Pancreatic tissue and elastase expression is
restored in Ptf1a-MO embryos co-injected with mouse Ptf1a.
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due to a dilution of the morpholino allowing newly generated
beta cells to develop. To address this possibility, we examined
insulin expression at the earlier tadpole stage 35 when it is first
detected. Similar to the results at later stages, we found insulin
expression reduced, but not completely absent (Figs. 7I–K),
thus arguing against a dilution of the morpholino. It is possible
that reduction of Ptf1a function more significantly affects
exocrine (acinar) differentiation and perhaps that lower levels
still allow the derivation of endocrine cells from the
uncommitted progenitor cells.
To determine if an incomplete block of Ptf1a was res-
ponsible for the partial inhibition in endocrine cell develop-
ment, we co-injected both morpholinos. To accurately compare
our results, we injected the same total amount of both mor-
pholinos (20 ng each) used with each single morpholino. 20 ng
of MO1 and 20 ng of MO2 (2MO) were co-injected into the
vegetal blastomeres of eight cell embryos. Similar to that seen
with each single morpholino, no pancreatic outgrowth was
evident; elastase expression was absent (Fig. 7D), and insulin
expression was reduced at stage 42 (Fig. 7H). Interestingly, in
contrast to the single morpholino injections, expression of
insulin was completely absent at early stage 35 demonstrating
that Ptf1a function is essential for initial specification of both
endocrine and exocrine cells (Fig. 7L). We confirmed insulin
expression differences quantitatively by real-time PCR analysis
of MO1-, MO2-, 2MO-injected and control embryos at stage
35. Four individual embryos were examined for each injection.
There was an average decrease in insulin expression of 3.5-
fold for single MO1- and MO2-injected embryos, whereas in
2MO-injected embryos there was an 18-fold reduction (Fig.
7Q). In all cases, single or double morpholino, we found liver
development occurred normally as marked by expression of
Xhex (Figs. 7M–P). The loss of insulin expression at early
stages and subsequent re-expression at later stages suggests
that in Xenopus Ptf1a is essential for the initial specification ofboth endocrine and exocrine cells, while its function is
dispensable for the generation of the later-appearing insulin
cells.
Mouse Ptf1a mRNA rescues pancreatic agenesis caused by
Xptf1a morpholino
To determine if the phenotype caused by the Ptf1a
morpholino is directly related to inhibition of endogenous
Ptf1a, we attempted to rescue the loss of pancreatic tissue and
acinar differentiation markers by co-expressing mouse Ptf1a
mRNA. Injection of 25 ng of MO2 leads to a complete loss of
ventral pancreatic tissue and persistence of a dorsal nub in 50%
of injected embryos (Fig. 8B). Co-injection of 300 pg of mPtf1a
mRNA rescued the loss of pancreatic tissue and acinar gene
expression. Fifty percent of rescued embryos developed a
normal sized pancreas with elastase expression (Fig. 8C). The
other 50% had a slightly enlarged pancreas with elastase
expression, similar to the Ptf1a overexpression phenotype (Fig.
8D). These results clearly demonstrate that the Ptf1a morpho-
lino phenotype is indeed due to inhibition of the endogenous
Xenopus Ptf1a mRNA.
Discussion
Despite the numerous studies pursuing loss-of-function
studies with pancreatic transcription factors, few have addressed
the sufficiency of these factors in activating the pancreatic
differentiation program in other cell types. In this paper, we
have used Xenopus transgenics and mRNA overexpression to
examine the functional ability of seven different pancreatic
transcription factors in converting liver to pancreas and found
that only one of these, Ptf1a-VP16, is sufficient. We also show
that, while the unmodified Ptf1a has no effect in liver, it is
sufficient to reprogram stomach/duodenum to pancreas. Last,
we have investigated the role of X. laevis Ptf1a in early
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proper development of both endocrine and exocrine pancreatic
lineages. These results establish Ptf1a as a central player in
directing pancreatic cell fate determination being both neces-
sary and sufficient.
Ptf1a is a master regulator of pancreatic cell fate
Much of the previous work on converting other cell types to
pancreas has focused on Pdx1 since in its absence the pancreas
does not form. Indeed, we showed that Pdx1-VP16 is sufficient
to convert liver to pancreas (Cao et al., 2004; Horb et al., 2003;
Li et al., 2005). The ability of other PTFs to convert liver to
pancreas has not been explored. Using our transgenic trans-
differentiation assay, we find that only one other transcription
factor, Ptf1a, has any activity to ectopically activate the Elas-
GFP transgene in Xenopus transgenics. The ability to convert
liver to pancreas would therefore seem to be limited to only
those transcription factors that function during the initial stages
of pancreas development prior to the division of endocrine and
exocrine progenitors. The fact that loss of Ptf1a or Pdx1 leads
to pancreas agenesis, while loss of the other PTFs affects only
certain endocrine lineages supports this notion. We have not,
however, thoroughly investigated every pancreatic transcription
factor, and it will be of interest to determine if this concept holds
true for other early acting lineage restricted transcription factors,
such as ngn3. Furthermore, it is possible that a whole series of
combinations of the various factors (twos, threes, etc.) might
reveal interesting conversion phenotypes consistent with the
ability of Ptf1a and Pdx1 to act early to engage these suites of
transcription factors in the correct order/combinations.
Our examination of the sufficiency of Ptf1a in converting
other endodermal cells into pancreas suggests that the addition
of VP16 (though enhancing transcriptional activation) actually
restricts Ptf1a activity and has revealed differential responses to
this transcription factor among distinct foregut tissues. Several
lines of evidence support this contention: (1) the unmodified
Ptf1a is sufficient to convert stomach/duodenum to pancreas at
organogenesis stages, whereas Ptf1a-VP16 has no such ability;
(2) Ptf1a-VP16 can only promote acinar cell fates, while the
unmodified Ptf1a promotes both endocrine and acinar cell fates;
and (3) even at earlier stages, prior to differentiation and orga-
nogenesis, Ptf1a-VP16 only promotes acinar cell fates. These
ideas do not however address the fact that the unmodified Ptf1a
is itself limited in function, such that it is unable to exert any
phenotypic effect in liver cells at any stage. We simply suggest
that the addition of VP16 restricts Ptf1a target specificity and/or
protein interactions to only those promoting acinar and not
endocrine differentiation. Therefore, the ability of Ptf1a to
promote either endocrine or acinar cell fates seems to be
determined by its partner protein interactions at different times
during embryogenesis. This implies that the intrinsic activity of
Ptf1a when expressed as a VP16 fusion is to convert liver, and
endoderm-generally, to acinar fates, while a version that does
not “bypass” its normal transcriptional complex build-up is able
to promote both acinar and endocrine cell fates. The finding that
Ptf1a can only convert posterior foregut tissues to pancreaswould therefore suggest that other coactivators are essential for
Ptf1a to bring about a fate change. Indeed, the fact that PTF1a is
part of a heterotrimeric complex and that it is regulated dif-
ferently depending on its interaction with partner proteins
supports this argument (Beres et al., 2006; Esni et al., 2004).
Identification of the different protein partners and down-
stream targets of Ptf1a and Ptf1a-VP16 will help elucidate how
pancreatic progenitors are directed down an endocrine or
acinar lineage. The fact that Ptf1a-VP16 is able to promote
acinar cell fate in early anterior endoderm and later liver cells
(but not stomach/duodenum) suggests that the same protein
partners are present throughout the anterior endoderm as in the
liver, and not in the posterior endoderm or the stomach and
duodenum. Of interest along these lines is the finding that
neither Ptf1a nor Ptf1a-VP16 overexpression in early embryos
has any effect on gastrulation and neurulation. In fact, we only
see a phenotype after stage 30. Based on results with other
transcription factors in Xenopus, one would have thought that
overexpression of a VP16 fusion would lead to early
developmental defects. The simplest interpretation is that the
necessary cofactors for Ptf1a are only present after stage 30.
However, since Ptf1a is a bHLH protein it should interact with
other bHLH proteins at all stages and interfere with their
function. Alternatively, since we are only injecting the mRNA
into vegetal blastomeres, it may be that the early endoderm
lacks the necessary bHLH cofactors. In seeming agreement
with this, overexpression of Ptf1a in ectoderm inhibits neuro-
genesis at early stages (Obata et al., 2001).
Two pathways to generate endocrine cells: Ptf1a dependent
and independent
Our results concur with previous data in zebrafish and mouse
demonstrating that Ptf1a is an essential regulator of acinar cell
development, whereas it is only required for the development of
a subset of endocrine cells. In zebrafish Ptf1a morphants no
exocrine pancreatic tissue develops, while early endocrine cell
development is normal. The development of a late-appearing
population of endocrine cells however does require Ptf1a (Lin
et al., 2004). Similarly, in Ptf1a mutant mice there is a complete
loss of acinar cells, with a dramatic reduction in all endocrine
cell types (Kawaguchi et al., 2002; Krapp et al., 1998). Here we
demonstrate that in Xenopus the initial specification of both
exocrine and endocrine cells is inhibited in Ptf1a morphants,
whereas a late-appearing population of insulin-positive cells is
unaffected. Our results are however in conflict with the recent
study examining Xenopus Ptf1a function during normal
development (Afelik et al., 2006). In their study, they come to
the opposite conclusion that Ptf1a function is not necessary for
early insulin-expressing cells but rather is essential for late-
appearing endocrine cells. In agreement with their data, we also
found normal development of early insulin-expressing cells in
single Ptf1a morpholino injections. In contrast, however, we
found that early-appearing insulin cells did not develop in our
double Ptf1a morphants. Furthermore, in both our single and
double Ptf1a morphants the late-appearing insulin population
always develops. The main difference between our studies and
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knockdown Ptf1a function. In agreement with this our results
demonstrating that the second splice morpholino effectively
inhibits splicing of the Ptf1a transcript also revealed that
splicing was not completely inhibited (see Fig. 7). This suggests
that either single morpholino, whether inhibiting translation or
splicing, is not completely effective in blocking Ptf1a and that a
combination of both is more effective. This explains why we
found effects on the early insulin-expressing population,
whereas the previous study did not. In combination, the results
from all three species would therefore suggest that there are two
pathways to generate endocrine cells: a Ptf1a-dependent and a
Ptf1a-independent pathway. This is entirely consistent with
the existence of a lower number of endocrine cells in the
pancreatic rudiment formed in Ptf1a-null mouse embryos.
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